This Review examines the molecular mechanisms by which DDR defects potentiate immunotherapy, including recent advances in DDR-targeted combination strategies and discusses mechanisms of resistance, offering a comprehensive perspective on exploiting DDR deficiencies for improved cancer treatment outcomes.
This review summarizes the major DDR pathways, their roles in tumor evolution and immune remodeling, and the rationale and limitations of combining DDR-targeted therapies with immunotherapy and discusses biomarker refinement, resistance mechanisms, and future strategies for translating genomic stress into durable antit...
A modular biomarker framework integrating genomic, functional, immune‐context, spatial and dynamic readouts to guide patient selection, treatment adaptation, and precision therapeutic decision‐making is proposed.
Yi-Huan Qiao, B. Kang, Jian Zhang et al.· MedComm· 0 citations
Homologous recombination deficiency (HRD) is a major genomic feature of several malignancies and provides a therapeutic rationale for DNA-damaging agents and PARP inhibitors. Beyond its role in genome instability, accumulating evidence suggests that HRD also reshapes the tumor microenvironment (TME). However, the immun...
Yi-Ting Yang, Yu-Jia Yin, Sheng-Xin Rong et al.· Cancer Metastasis Review· 0 citations
This review integrates the major tumor-intrinsic and tumor-extrinsic mechanisms that drive ICI resistance, including defective antigen presentation, impaired interferon signaling, oncogenic and epigenetic immune escape programs, metabolic rewiring, suppressive myeloid and stromal circuits, abnormal vasculature, and pro...
R. Karataş, Yaren Alras, Sarenur Teki̇ner et al.· Immunologic research· 0 citations
The DNA damage response (DDR) network maintains genomic integrity, functions as a signaling hub that viruses exploit to drive pathogenesis, and constitutes a central interface between viral infection and host cell fate. This review discusses the molecular mechanisms by which viruses subvert host DDR pathways, with an e...
Melanoma is characterised by profound immune evasion, and although immune checkpoint inhibitors (ICIs) have transformed clinical management, durable responses remain limited to a subset of patients. Therapies that induce immunogenic cell death (ICD) can enhance anti-tumour immunity by converting dying tumour cells into...
Lisa Van der Heyden, Steve Vanlanduit, E. Smits et al.· Biomedicines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
